(+)-PD 128907 HCl | CAS#300576-59-4 | D3 receptor agonist

MedKoo Cat#: 563076 | Name: (+)-PD 128907 HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

(+)-PD 128907 is a potent agonist of the dopamine 3 (D3) receptor. (+)-PD 128907 shows selectivity for D3 over D2 and D4 receptors (Kis = 1.2 and 7 µM, respectively). PD 128907 inhibits stimulated pyloric relaxation and spontaneous gastric emptying. PD 128907 holds promise as useful agents for treatment of gastric motility disorders.

Chemical Structure

(+)-PD 128907 HCl

CAS#300576-59-4 (HCl)

Theoretical Analysis

MedKoo Cat#: 563076

Name: (+)-PD 128907 HCl

CAS#: 300576-59-4 (HCl)

Chemical Formula: C14H20ClNO3

Exact Mass: 285.1132

Molecular Weight: 285.76

Elemental Analysis: C, 58.84; H, 7.05; Cl, 12.41; N, 4.90; O, 16.80

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 290.00
10mg	USD 470.00
25mg	USD 790.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

23594-64-9 (free base) 300576-59-4 (HCl)

Synonym

(+)-PD 128907 HCl; PD-128907; PD128907; PD128907 hydrochloride; PBPO; PBTO;

IUPAC/Chemical Name

(4aS,10bS)-4-Propyl-3,4a,5,10b-tetrahydro-2H-chromeno[4,3-b][1,4]oxazin-9-ol Hydrochloride

InChi Key

DCFXOTRONMKUJB-KYSPHBLOSA-N

InChi Code

InChI=1S/C14H19NO3.ClH/c1-2-5-15-6-7-17-14-11-8-10(16)3-4-13(11)18-9-12(14)15;/h3-4,8,12,14,16H,2,5-7,9H2,1H3;1H/t12-,14-;/m0./s1

SMILES Code

OC1=CC([C@]2([H])OCCN(CCC)[C@@]2([H])CO3)=C3C=C1.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 285.76 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kehr J, Wang FH, Ichinose F, Yoshitake S, Farkas B, Kiss B, Adham N. Preferential Effects of Cariprazine on Counteracting the Disruption of Social Interaction and Decrease in Extracellular Dopamine Levels Induced by the Dopamine D3 Receptor Agonist, PD-128907 in Rats: Implications for the Treatment of Negative and Depressive Symptoms of Psychiatric Disorders. Front Psychiatry. 2022 Jan 12;12:801641. doi: 10.3389/fpsyt.2021.801641. PMID: 35095615; PMCID: PMC8789685. 2: Xu P, Huang S, Mao C, Krumm BE, Zhou XE, Tan Y, Huang XP, Liu Y, Shen DD, Jiang Y, Yu X, Jiang H, Melcher K, Roth BL, Cheng X, Zhang Y, Xu HE. Structures of the human dopamine D3 receptor-Gi complexes. Mol Cell. 2021 Mar 18;81(6):1147-1159.e4. doi: 10.1016/j.molcel.2021.01.003. Epub 2021 Feb 5. PMID: 33548201. 3: Robles-Gómez AA, Vega AV, Florán B, Barral J. Differential calcium channel- mediated dopaminergic modulation in the subthalamonigral synapse. Synapse. 2020 Jul;74(7):e22149. doi: 10.1002/syn.22149. Epub 2020 Feb 5. PMID: 31975491. 4: Huang M, He W, Kiss B, Farkas B, Adham N, Meltzer HY. The Role of Dopamine D3 Receptor Partial Agonism in Cariprazine-Induced Neurotransmitter Efflux in Rat Hippocampus and Nucleus Accumbens. J Pharmacol Exp Ther. 2019 Nov;371(2):517-525. doi: 10.1124/jpet.119.259879. Epub 2019 Sep 11. PMID: 31511365. 5: Lanza K, Chemakin K, Lefkowitz S, Saito C, Chambers N, Bishop C. Reciprocal cross-sensitization of D1 and D3 receptors following pharmacological stimulation in the hemiparkinsonian rat. Psychopharmacology (Berl). 2020 Jan;237(1):155-165. doi: 10.1007/s00213-019-05353-6. Epub 2019 Aug 21. PMID: 31435690. 6: Lanza K, Meadows SM, Chambers NE, Nuss E, Deak MM, Ferré S, Bishop C. Behavioral and cellular dopamine D1 and D3 receptor- mediated synergy: Implications for L-DOPA-induced dyskinesia. Neuropharmacology. 2018 Aug;138:304-314. doi: 10.1016/j.neuropharm.2018.06.024. Epub 2018 Jun 21. PMID: 29936243; PMCID: PMC9380415. 7: Delcourte S, Ashby CR Jr, Rovera R, Kiss B, Adham N, Farkas B, Haddjeri N. The novel atypical antipsychotic cariprazine demonstrates dopamine D2 receptor-dependent partial agonist actions on rat mesencephalic dopamine neuronal activity. CNS Neurosci Ther. 2018 Dec;24(12):1129-1139. doi: 10.1111/cns.12867. Epub 2018 May 4. PMID: 29729086; PMCID: PMC6282959. 8: Zhu Y, Wang Y, Lai J, Wei S, Zhang H, Yan P, Li Y, Qiao X, Yin F. Dopamine D1 and D3 Receptors Modulate Heroin-Induced Cognitive Impairment through Opponent Actions in Mice. Int J Neuropsychopharmacol. 2017 Mar 1;20(3):257-268. doi: 10.1093/ijnp/pyw099. PMID: 27815417; PMCID: PMC5408975. 9: McGinnis MM, Siciliano CA, Jones SR. Dopamine D3 autoreceptor inhibition enhances cocaine potency at the dopamine transporter. J Neurochem. 2016 Sep;138(6):821-9. doi: 10.1111/jnc.13732. Epub 2016 Aug 15. PMID: 27393374; PMCID: PMC5017912. 10: Chen X, Liu Y, Wang WE, Chen C, Ren H, Zheng S, Zhou L, Zeng C. Effect of D3 dopamine receptor on dopamine D4 receptor expression and function in renal proximal tubule cells from Wistar-Kyoto rats and spontaneously hypertensive rats. J Hypertens. 2016 Aug;34(8):1599-606. doi: 10.1097/HJH.0000000000000986. PMID: 27254310. 11: Kotani M, Enomoto T, Murai T, Nakako T, Iwamura Y, Kiyoshi A, Matsumoto K, Matsumoto A, Ikejiri M, Nakayama T, Ogi Y, Ikeda K. The atypical antipsychotic blonanserin reverses (+)-PD-128907- and ketamine-induced deficit in executive function in common marmosets. Behav Brain Res. 2016 May 15;305:212-7. doi: 10.1016/j.bbr.2016.02.031. Epub 2016 Mar 9. PMID: 26970575. 12: Kotani M, Kiyoshi A, Murai T, Nakako T, Matsumoto K, Matsumoto A, Ikejiri M, Ogi Y, Ikeda K. The dopamine D1 receptor agonist SKF-82958 effectively increases eye blinking count in common marmosets. Behav Brain Res. 2016 Mar 1;300:25-30. doi: 10.1016/j.bbr.2015.11.028. Epub 2015 Dec 7. PMID: 26675887. 13: Huang M, Kwon S, Oyamada Y, Rajagopal L, Miyauchi M, Meltzer HY. Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement. Pharmacol Biochem Behav. 2015 Nov;138:49-57. doi: 10.1016/j.pbb.2015.09.011. Epub 2015 Sep 14. PMID: 26383990. 14: Kohnomi S, Konishi S. Multiple actions of a D₃ dopamine receptor agonist, PD128907, on GABAergic inhibitory transmission between medium spiny neurons in mouse nucleus accumbens shell. Neurosci Lett. 2015 Jul 23;600:17-21. doi: 10.1016/j.neulet.2015.05.056. Epub 2015 May 29. PMID: 26033184. 15: Wang Z, Guan W, Han Y, Ren H, Tang X, Zhang H, Liu Y, Fu J, He D, Asico LD, Jose PA, Zhou L, Chen L, Zeng C. Stimulation of Dopamine D3 Receptor Attenuates Renal Ischemia-Reperfusion Injury via Increased Linkage With Gα12. Transplantation. 2015 Nov;99(11):2274-84. doi: 10.1097/TP.0000000000000762. PMID: 25989500; PMCID: PMC4618723. 16: Carnicella S, Drui G, Boulet S, Carcenac C, Favier M, Duran T, Savasta M. Implication of dopamine D3 receptor activation in the reversion of Parkinson's disease-related motivational deficits. Transl Psychiatry. 2014 Jun 17;4(6):e401. doi: 10.1038/tp.2014.43. PMID: 24937095; PMCID: PMC4080324. 17: Cote SR, Chitravanshi VC, Bleickardt C, Sapru HN, Kuzhikandathil EV. Overexpression of the dopamine D3 receptor in the rat dorsal striatum induces dyskinetic behaviors. Behav Brain Res. 2014 Apr 15;263:46-50. doi: 10.1016/j.bbr.2014.01.011. Epub 2014 Jan 23. PMID: 24462727. 18: Cote SR, Kuzhikandathil EV. In vitro and in vivo characterization of the agonist-dependent D3 dopamine receptor tolerance property. Neuropharmacology. 2014 Apr;79:359-67. doi: 10.1016/j.neuropharm.2013.11.023. Epub 2013 Dec 5. PMID: 24316466. 19: Tournier BB, Steimer T, Millet P, Moulin-Sallanon M, Vallet P, Ibañez V, Ginovart N. Innately low D2 receptor availability is associated with high novelty-seeking and enhanced behavioural sensitization to amphetamine. Int J Neuropsychopharmacol. 2013 Sep;16(8):1819-34. doi: 10.1017/S1461145713000205. Epub 2013 Apr 10. PMID: 23574629. 20: Gil-Mast S, Kortagere S, Kota K, Kuzhikandathil EV. An amino acid residue in the second extracellular loop determines the agonist-dependent tolerance property of the human D3 dopamine receptor. ACS Chem Neurosci. 2013 Jun 19;4(6):940-51. doi: 10.1021/cn3002202. Epub 2013 Mar 21. PMID: 23477444; PMCID: PMC3689203.